SIBNMEDIUM SIGNALOPERATIONAL10-K

SIBN significantly improved operational performance with 95% reduction in cash burn while achieving 21.5% revenue growth and expanding their product positioning from a focused sacroiliac joint company to a broader procedural solutions leader.

The dramatic improvement in operating cash flow from -$12.4M to -$675K demonstrates meaningful progress toward profitability while maintaining strong revenue growth. The strategic repositioning language suggests management is broadening their market opportunity beyond their traditional niche, which could support sustained growth but also indicates increased competitive positioning requirements.

Comparing 2026-02-24 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

SIBN delivered strong operational improvements across the board, with revenue growing 21.5% to $67.3M and gross profit expanding proportionally to $159.9M. The company dramatically reduced cash burn by 95% while maintaining positive cash position growth to $42.2M and building inventory by 25.2% to support growth. Net losses improved significantly from -$30.9M to -$18.9M, indicating the company is moving toward profitability while successfully scaling the business.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+94.6%
-$12.4M→-$675K

Operating cash flow surged 94.6% — exceptional cash generation, highest quality earnings signal.

Share Buybacks
Cash Flow
-47.9%
$73K→$38K

Buyback activity reduced 47.9% — capital being redeployed elsewhere or cash conservation underway.

Net Income
P&L
+38.8%
-$30.9M→-$18.9M

Net income grew 38.8% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+36.6%
-$35.2M→-$22.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Inventory
Balance Sheet
+25.2%
$27.1M→$33.9M

Inventory built 25.2% — monitor whether demand supports this build or if write-downs may follow.

Interest Expense
P&L
+22.8%
$2.8M→$3.5M

Interest costs rose 22.8% — monitor debt levels and coverage ratio in rising rate environment.

Revenue
P&L
+21.5%
$55.4M→$67.3M

Revenue growing 21.5% — solid top-line momentum, watch margins for quality of growth.

Gross Profit
P&L
+21%
$132.1M→$159.9M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Cash & Equivalents
Balance Sheet
+20.9%
$34.9M→$42.2M

Cash grew 20.9% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-25
ADDED
Overview We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation.
As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we have developed a deep competency in addressing the challenges of low-density bone in the sacrum.
With our additive manufacturing, or 3D-printing, experience developed in sacroiliac fusion, we have established a technology platform that now extends to meet critical unmet needs in thoracolumbar fixation and fusion and pelvic trauma.
As of December 31, 2025, over 140,000 procedures have been performed using our products since we introduced iFuse in 2009.
In the European Economic Areas, iFuse, iFuse 3D and iFuse TORQ have been CE marked for applications in sacroiliac joint dysfunction, adult spinal deformity and pelvic fracture fixation.
+7 more — sign up free →
REMOVED
Overview We are a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy.
Leveraging our knowledge of pelvic anatomy and biomechanics, we have pioneered proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures.
As of December 31, 2024, over 115,000 procedures have been performed using our products by over 4,300 physicians in the United States and 38 other countries since we introduced iFuse in 2009.
In May 2023, we received a total of $83.7 million of net proceeds from the offering of 3,775,000 shares of our common stock, and the exercise of the underwriter's option to purchase an additional 566,250 shares of our common stock, at a public offering price of $22.00 per share.
Of these shares, 272,753 shares were offered by a selling stockholder, and we did not receive any proceeds from the sale by the selling stockholder.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →